Mentions
1
Across all reports
Quality Score
15/ 100
New
First Seen
May 25, 2026
Indexed in atlas
Last Seen
4h ago
Most recent reference
Positioning
Synthesized from 1 mentionIktos offers AI-powered software for generative chemistry, retrosynthesis, and synthetic planning, enabling pharmaceutical companies to design novel small molecules and optimize their synthesis routes. Its platform leverages machine learning to accelerate drug discovery, with established partnerships in the pharma industry.
Strengths
4 cited- AI-driven generative chemistry platform
- Focus on small molecule discovery
- Partnerships with pharmaceutical companies
- Covers retrosynthesis and synthetic planning
Weaknesses
4 cited- Narrow focus on small molecules
- Limited to early-stage drug discovery
- Dependence on pharma partnerships
- No visible pricing or self-service option
Recent mentions
Showing 1 of 1- direct4h ago
AI-Native Discovery Engine for Drug Discovery
nativediscoveryenginedrug
Validate something like Iktos
Use Iktos as a starting point and let Unycorn map adjacent opportunities, underserved segments, and feature gaps worth pursuing.